Loading…
Legacy Pharmaceutical Packaging LLC, a drug manufacturing and repackaging facility in Missouri, violated Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals during an April 2022 FDA inspection. The company failed to thoroughly investigate unexplained discrepancies and batch failures, including a critical failure to adequately investigate foreign tablets found in drug products—a serious concern given that the firm repackages and relabels numerous finished drugs and controlled substances where prevention of mix-ups is paramount. The violations rendered the company's drug products adulterated under federal law due to both non-conforming manufacturing methods and controls, and preparation under insanitary conditions that could result in contamination or health hazards.